New minimally invasive device may soon replace endoscopy for Barrett's esophagus diagnosis
the ONA take:
According to a new study published in the journal PLOS Medicine, reseearchers from the University of Cambridge MRC Cancer Unit in Cambridge, United Kingdom, have found that a new minimally invasive test can be used to identify patients with reflux symptoms to diagnose Barrett's esophagus rather than be referred for endoscopy for diagnosis.
For the study, researchers sought to evaluate the accuracy, safety, and acceptability of the test compared with endoscopy for the diagnosis of Barrett's esophagus, a disorder characterized by an abnormal change in the cells of the lower part of the esophagus that is a risk factor for the development of esophageal cancer.
Researchers enrolled 1,110 patients from various hospitals in the United Kingdom who were referred for a diagnostic endoscopy for symptoms of dyspepsia and reflux symptoms.
Results showed that the new minimally invasive test accurately diagnosed 79.7% of the 647 patients with endoscopically diagnosed Barrett's esophagus, and correctly identified 92.4% of 463 of those unaffected by Barrett's esophagus as not having Barrett's esophagus.
Researchers found that the test had an 87.2% sensitivity when patients had a circumferential Barrett's segments over 3cm. Most patients were able to swallow the device without issues and no adverse events were observed.
A new minimally invasive test can be used to identify patients with reflux symptoms to diagnose Barrett's esophagus.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|